ACAD Q4 2025 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$284M+9.4% YoY

Gross Profit

$258M90.8% margin

Operating Income

$17M6.1% margin

Net Income

$274M96.3% margin

EPS (Diluted)

$1.60

QoQ Revenue Growth

+1.9%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$53M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$337M

Stockholders' Equity

$1.2B

Cash & Equivalents

$820M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$284M	$260M	+9.4%
Gross Profit	$258M	$238M	+8.4%
Operating Income	$17M	$154M	-88.7%
Net Income	$274M	$144M	+90.3%